Jed Latkin, COO and CFO at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB), bought 7,600 shares at $0.44 ($3K) on 2017-05-30, disclosed to the SEC on 2017-05-31.
Open-market purchase of $3k NAVB by COO and CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| NAVB | BUY | 2019-05-17 | $4K | — | Filing → |
| NAVB | BUY | 2019-05-15 | $10K | — | Filing → |
| NAVB | BUY | 2017-05-23 | $11K | — | Filing → |